Reactions 1680, p198 - 2 Dec 2017 Hepatotoxicity and bone marrow suppression: 2 case reports In a study of 30 patients, two patients [ages and sexes not stated] were described, who developed hepatotoxicity and hepatotoxicity with bone marrow suppression, respectively during treatment with methotrexate and leflunomide. The patients, who had a history of rheumatoid arthritis, were undergoing treatment with methotrexate and leflunomide [routes and dosages not stated] and subsequently, one patient developed hepatotoxicity whereas, another patient developed hepatotoxicity with bone marrow suppression [times to reactions onsets not stated]. The patient’s methotrexate and leflunomide were stopped. The patients condition returned to normal within one month of methotrexate and leflunomide discontinuation. Author comment: "Many Rheumatologists worldwide are skeptical to use of this combination due to possible side effects like hepatotoxicity and bone marrow suppression." Doshi BS, et al. Study of efficacy and safety of methotrexate and leflunomide combination therapy in patients with rheumatoid arthritis (RA)- An audit. Indian Journal of Rheumatology 9 (Suppl.): S25-S26 abstr. P66, No. 5, Jul 2014. Available from: URL: http://doi.org/10.1016/j.injr.2014.10.005 [abstract] - India 803284784 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera